Stockreport

Nuvation Bio (NUVB) Generates $62.9M Annual Revenue Following Successful Erozi Launch [Yahoo! Finance]

Nuvation Bio Inc. Class A  (NUVB) 
PDF March 2, Nuvation Bio (NUVB) reported a pivotal 2025 marked by the FDA approval and rapid commercial launch of Ibtrozi (Taletrectinib) for ROS1-positive non-small cell l [Read more]